港股开盘：恒指涨0.17%、科指涨0.21%，创新药及有色金属概念股走高，内房股表现活跃

Market Overview - US stock market continues to rise with increasing expectations of interest rate cuts, leading to a slight opening increase in Hong Kong stocks, with the Hang Seng Index up 0.17% at 25,804.01 points [1] - Major technology stocks mostly rose, with Alibaba down 0.33%, Tencent down 0.16%, JD.com up 0.61%, Xiaomi up 0.3%, NetEase up 0.32%, Meituan up 0.94%, and Kuaishou up 0.07% [1] - The innovative drug concept opened high, with Gilead Sciences up over 3% and BeiGene up 3.1% [1] - Real estate stocks were active, with China Oceanwide Holdings up over 1% [1] - The non-ferrous metals sector performed actively, with Chalco International up 7.17% and Luoyang Molybdenum up 3.43% [1] - Airline stocks opened lower, with China Eastern Airlines down over 1% [1] - Robotics concept stocks opened high, with Sanhua Intelligent Control up 5.67% and Yujian up 4.06% [1] Company News - InnoCare Pharma (02577.HK) has reached a strategic cooperation agreement with ON Semiconductor to accelerate the development of the GaN industry ecosystem [2] - The collaboration aims to integrate InnoCare's advanced GaN manufacturing capabilities with ON Semiconductor's expertise in system packaging and integration, potentially generating hundreds of millions in GaN sales over the next few years [2] - Agile Group (03383.HK) reported a total pre-sale amount of approximately 8.08 billion, a year-on-year decrease of 45.2% [3] - Jingrui Holdings (01862.HK) reported a cumulative contract sales amount of approximately 876 million, a year-on-year decrease of 54.1% [4] - China Aluminum International (02068.HK) announced that its subsidiary won a bid for a new 394,000 tons/year electrolytic aluminum project in Shanxi, with a total contract price of 3.03 billion [4] - Stone Pharmaceutical Group (01093.HK) received clinical trial approval for a selective 5-HT2A receptor agonist in the US [5] - Fosun Pharma (02196.HK) received clinical trial approval for its subsidiary's FXS887 tablets [6] - Zai Lab (02617) had its Tislelizumab tablets included in the priority review list by the National Medical Products Administration [7] - Deking Pharma (06996) received approval in Hong Kong for its Hivio® to treat two new indications: multiple myeloma and diffuse large B-cell lymphoma [7] - Kaisa Group (01813) has postponed its liquidation hearing to December 8 [8] Industry Insights - According to CCB International, domestic demand policies are being promoted, and the market is focusing on the "New Year" expectations [9] - After the consolidation in November, the Hong Kong stock market is expected to welcome a layout window for the year-end rally in December [9] - The focus is shifting from external environments to internal policies, with attention on the Central Economic Work Conference scheduled for mid-December [9] - Tianfeng Securities reported that most northern provinces have begun implementing staggered production during the heating season, with over 85% of clinker lines in a shutdown state [9] - The overall staggered production efforts have strengthened, with Hunan planning a month-long shutdown in December due to environmental pressures [9] - The bottom profitability support for cement is strong in the short term, with head enterprises starting to address overproduction capacity indicators [9]